Halofantrine is an antimalarial drug which is widely prescribed for th
e treatment of infections with chloroquine-resistant strains of Plasmo
dium falciparum. Chemically, it is a phenanthrene methanol, belonging
to the aryl-amino-alcohol family. It has recently been recognized that
this drug may induce rare but serious, cardiotoxic effects, including
lengthening of the QTc interval, 'torsode de pointes' and induction o
f late ventricular potentials. These events are thought to be related
to a quinidine-like action of the drug. In addition, severe haemolytic
accidents have been reported, mimicking blackwater fever and indicati
ng an immunological process. As a result of these side-effects, new gu
idelines for prescription and more cautious use of halofantrine, parti
cularly as a stand-by treatment for febrile access among travellers, a
re required.